Yuval Konstantino
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Yuval Konstantino has a total of 179 co-authors. Here are the top co-authors by number of shared publications:
Moti Haim
Faculty of Health Sciences, Ben-Gurion University of the Negev, Beer Sheva, Israel
15 shared publications- Moti Haim
Cardiology Department, Soroka University Hospital, Beer Sheva 8410101, Israel
7 shared publications Sergiy Bereza
Faculty of Health Sciences, Ben-Gurion University of the Negev, Beer Sheva, Israel
7 shared publicationsAlexander Battler
5 shared publicationsGuy Amit
Division of Cardiology, Department of Medicine, McMaster University, Hamilton, Canada
4 shared publicationsMahmoud Suleiman
Eyal Ofer Heart Hospital, Cardiac Electrophysiology and Pacing, Rambam Health Care Campus, Haifa, Israel
4 shared publications
Latest Publications
- 25 April 2026
- Published by Springer Nature in Journal of Interventional Cardiac Electrophysiology
- Vol. 69 (7) , 1803-1811
Postoperative antibiotic prophylaxis following cardiac implantable electronic device implantation and the risk of device infection
- 25 April 2026
- Published by Springer Nature in Journal of Interventional Cardiac Electrophysiology
- Vol. 69 (7) , 1803-1811
Postoperative antibiotic prophylaxis following cardiac implantable electronic device implantation and the risk of device infection
- Open Access
- 25 October 2025
- Published by Elsevier in Heart Rhythm O2
- Vol. 7 (1) , 27-36
Does obesity affect atrial fibrillation ablation outcomes? Insights from a national atrial fibrillation catheter ablation registry: One-year follow-up
- 25 October 2025
- Published by Elsevier in Heart Rhythm O2
- Vol. 7 (1) , 27-36
Open AccessDoes obesity affect atrial fibrillation ablation outcomes? Insights from a national atrial fibrillation catheter ablation registry: One-year follow-up
- Open Access
- 3 September 2025
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 14 (17) , 6227
Outcomes of Atrial Fibrillation Ablation in Patients with Chronic Kidney Disease
Background: Limited and inconsistent information exist about how kidney function affects the outcomes of ablation procedures in patients with atrial fibrillation (AF). Therefore, the aim of this study was to investigate the effectiveness and safety of AF ablation in a large national study across groups classified by varying levels of estimated glomerular filtration rates (eGFRs). Methods: The Israeli Catheter Ablation Registry (ICAR) is a prospective, multicenter cohort that includes patients who underwent pulmonary vein isolation (PVI) during the years 2019–2021 for the treatment of AF. Primary study endpoints were the recurrence of AF and the need for repeat ablation at 12 months. Secondary endpoints were rehospitalization and procedural complications after AF ablation. Results: Between January 2019 and December 2021, 1002 AF patients underwent PVI. Baseline creatinine was available in 929 patients, which comprised the study cohort. Of these patients, 226 (24%) had preserved eGFR (>90 mL/min/1.73 m2), 511 (55%) had mildly reduced eGFR (60–89 mL/min/1.73 m2), and 192 (21%) had moderately to severely reduced eGFR (2). Patients with moderately to severely reduced eGFR were generally older and more likely to be female. There were no clinically meaningful differences in the use of antiarrhythmic medications among the eGFR groups, either before or after PVI. There were no significant differences in 12-month AF recurrence rates among the three study groups: 30%, 32%, and 40% in patients with preserved eGFR, mild, and moderately to severely reduced eGFR, respectively (p = 0.1). The one-year rehospitalization rate was higher in patients with moderately to severely reduced eGFR: 19%, 24%, and 32% in patients with preserved eGFR, mild, and moderately to severely reduced eGFR, respectively (p = 0.01). Periprocedural complications were infrequent across all the eGFR groups. Patients with an eGFR of 2 were underrepresented (<1%), limiting applicability to this group. Conclusions: PVI is a safe and effective procedure that should be considered for CKD patients with AF who are deemed as suitable for the intervention, even in the presence of declined eGFR values. Future studies are still needed to evaluate the safety and effectiveness of the procedure in individuals with severely reduced eGFR or end-stage kidney disease.
- 3 September 2025
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 14 (17) , 6227
Open AccessOutcomes of Atrial Fibrillation Ablation in Patients with Chronic Kidney Disease
Background: Limited and inconsistent information exist about how kidney function affects the outcomes of ablation procedures in patients with atrial fibrillation (AF). Therefore, the aim of this study was to investigate the effectiveness and safety of AF ablation in a large national study across groups classified by varying levels of estimated glomerular filtration rates (eGFRs). Methods: The Israeli Catheter Ablation Registry (ICAR) is a prospective, multicenter cohort that includes patients who underwent pulmonary vein isolation (PVI) during the years 2019–2021 for the treatment of AF. Primary study endpoints were the recurrence of AF and the need for repeat ablation at 12 months. Secondary endpoints were rehospitalization and procedural complications after AF ablation. Results: Between January 2019 and December 2021, 1002 AF patients underwent PVI. Baseline creatinine was available in 929 patients, which comprised the study cohort. Of these patients, 226 (24%) had preserved eGFR (>90 mL/min/1.73 m2), 511 (55%) had mildly reduced eGFR (60–89 mL/min/1.73 m2), and 192 (21%) had moderately to severely reduced eGFR (2). Patients with moderately to severely reduced eGFR were generally older and more likely to be female. There were no clinically meaningful differences in the use of antiarrhythmic medications among the eGFR groups, either before or after PVI. There were no significant differences in 12-month AF recurrence rates among the three study groups: 30%, 32%, and 40% in patients with preserved eGFR, mild, and moderately to severely reduced eGFR, respectively (p = 0.1). The one-year rehospitalization rate was higher in patients with moderately to severely reduced eGFR: 19%, 24%, and 32% in patients with preserved eGFR, mild, and moderately to severely reduced eGFR, respectively (p = 0.01). Periprocedural complications were infrequent across all the eGFR groups. Patients with an eGFR of 2 were underrepresented (<1%), limiting applicability to this group. Conclusions: PVI is a safe and effective procedure that should be considered for CKD patients with AF who are deemed as suitable for the intervention, even in the presence of declined eGFR values. Future studies are still needed to evaluate the safety and effectiveness of the procedure in individuals with severely reduced eGFR or end-stage kidney disease.
- Open Access
- 10 June 2025
- Published by Wiley in Pacing and Clinical Electrophysiology
- Vol. 48 (8) , 870-873
Dual Tachycardia Followed by Tachycardia With Atrioventricular Block: What Is the Mechanism and What Does It Prove?
- 10 June 2025
- Published by Wiley in Pacing and Clinical Electrophysiology
- Vol. 48 (8) , 870-873
Open AccessDual Tachycardia Followed by Tachycardia With Atrioventricular Block: What Is the Mechanism and What Does It Prove?
- Open Access
- 5 February 2025
- Published by Oxford University Press (OUP) in EP Europace
- Vol. 27 (2)
Comparative analysis of anaesthesia modalities in pulmonary vein isolation: insights from a prospective multicentre registry
Aims: Atrial fibrillation (AF), the most common sustained arrhythmia in adults, is increasing in prevalence globally. Catheter ablation (CA), particularly pulmonary vein isolation (PVI), is a key treatment option. Pulmonary vein isolation can be performed using different energy sources, including cryoballoon ablation (CBA), radiofrequency ablation (RFA), or pulse field ablation. Anaesthesia modalities for these procedures include general anaesthesia (GA), deep sedation (DS), and conscious sedation (CS). However, the optimal anaesthesia modality remains unclear, as previous studies have shown mixed outcomes. This study aims to compare the safety and efficacy of different anaesthesia modalities in PVI. Methods and results: This prospective, multicentre study, based on the Israeli Catheter Ablation Registry, evaluated the impact of different anaesthesia modalities on procedural outcomes and safety in AF ablation. Data from 1002 patients who underwent PVI between January 2019 and December 2021 across 14 centres were analysed. Patients were stratified by anaesthesia modality—CS vs. GA, with the latter encompassing DS. Key outcomes, including AF recurrence, procedural complications, and success rates, were evaluated over a 24-month follow-up period. Additionally, a sensitivity analysis was performed for the subgroup of patients who underwent CBA. Of the 1002 patients, 53% received GA, 6.3% DS, and 40% CS, with CBA used in 84% of cases. Complete PVI was achieved in 91% of patients, with comparable success rates observed between CS and GA groups. No significant differences were found between CS and GA modalities in terms of AF recurrence rates at 12 months (15% vs. 16%) and 24 months (19.5% vs. 21.2%), or in 12-month rehospitalization rates (19.8% vs. 16.5%). Sensitivity analysis of the CBA subgroup yielded similar results, with no significant differences in AF recurrence, complications, or procedural duration between CS and GA modalities. Conclusion: Conscious sedation is as safe and effective as general anaesthesia in AF ablation, particularly with cryoablation. The choice of anaesthesia appears to be driven by patient characteristics and institutional factors without affecting long-term outcomes such as AF recurrence or complication rates.
- 5 February 2025
- Published by Oxford University Press (OUP) in EP Europace
- Vol. 27 (2)
Open AccessComparative analysis of anaesthesia modalities in pulmonary vein isolation: insights from a prospective multicentre registry
Aims: Atrial fibrillation (AF), the most common sustained arrhythmia in adults, is increasing in prevalence globally. Catheter ablation (CA), particularly pulmonary vein isolation (PVI), is a key treatment option. Pulmonary vein isolation can be performed using different energy sources, including cryoballoon ablation (CBA), radiofrequency ablation (RFA), or pulse field ablation. Anaesthesia modalities for these procedures include general anaesthesia (GA), deep sedation (DS), and conscious sedation (CS). However, the optimal anaesthesia modality remains unclear, as previous studies have shown mixed outcomes. This study aims to compare the safety and efficacy of different anaesthesia modalities in PVI. Methods and results: This prospective, multicentre study, based on the Israeli Catheter Ablation Registry, evaluated the impact of different anaesthesia modalities on procedural outcomes and safety in AF ablation. Data from 1002 patients who underwent PVI between January 2019 and December 2021 across 14 centres were analysed. Patients were stratified by anaesthesia modality—CS vs. GA, with the latter encompassing DS. Key outcomes, including AF recurrence, procedural complications, and success rates, were evaluated over a 24-month follow-up period. Additionally, a sensitivity analysis was performed for the subgroup of patients who underwent CBA. Of the 1002 patients, 53% received GA, 6.3% DS, and 40% CS, with CBA used in 84% of cases. Complete PVI was achieved in 91% of patients, with comparable success rates observed between CS and GA groups. No significant differences were found between CS and GA modalities in terms of AF recurrence rates at 12 months (15% vs. 16%) and 24 months (19.5% vs. 21.2%), or in 12-month rehospitalization rates (19.8% vs. 16.5%). Sensitivity analysis of the CBA subgroup yielded similar results, with no significant differences in AF recurrence, complications, or procedural duration between CS and GA modalities. Conclusion: Conscious sedation is as safe and effective as general anaesthesia in AF ablation, particularly with cryoablation. The choice of anaesthesia appears to be driven by patient characteristics and institutional factors without affecting long-term outcomes such as AF recurrence or complication rates.
- Open Access
- 27 September 2024
- Published by Elsevier in Heart Rhythm
- Vol. 5 (12) , 873-882
A proposed algorithm for management of patients with left bundle branch block post-TAVR: 1-year follow-up
- 27 September 2024
- Published by Elsevier in Heart Rhythm
- Vol. 5 (12) , 873-882
Open AccessA proposed algorithm for management of patients with left bundle branch block post-TAVR: 1-year follow-up
- Open Access
- 24 May 2024
- Published by Oxford University Press (OUP) in EP Europace
- Vol. 26 (Supplement)
Electrophysiology-guided algorithm for patients with conduction abnormalities post TAVR: one-year follow-up
Introduction: Transcatheter aortic valve replacement (TAVR) revolutionized the treatment of aortic stenosis [1]. Although TAVR is an effective treatment for AS patients, it is associated with high incidence of new-onset conduction disturbances and pacemaker implantations. The two most common conduction disturbances after TAVR are new onset left bundle branch block (LBBB) and high-degree atrioventricular block (HDAVB) [2]. While patients with HDAVB require a permanent pacemaker implantation (PPM), the management of LBBB is not completely established yet. According to the ESC 2021 guidelines, a PPM is indicated in patients with persistent HDAVB or new onset alternating BBB after TAVR. Yet, the recommendations regarding other conduction abnormalities are not well defined. In patients with persistent new onset LBBB, ambulatory continuous ECG monitoring or electrophysiology study (EPS) are recommended [3]. Purpose: To evaluate the clinical outcomes of patients with conduction disorders after TAVR who were managed according to electrophysiology-guided algorithm (Figure 1), including mortality, late pacemaker’s implantations, and heart failure hospitalizations. Predictors of periprocedural LBBB and HDAVB were also assessed. Methods: Retrospective population-based cohort study including all patients who developed new onset LBBB after TAVR at a tertiary University Medical Center from October 1, 2018, to December 31, 2022, and were managed according to specific electrophysiology-guided algorithm. Results: The study cohort included 230 consecutive patients who underwent TAVR. Mean age was 80.3 and 56.5% were females (Figure 2). Twenty patients (8.7%) developed HDAVB and required a PPM, whereas 40 patients (17.4%) developed persistent LBBB. According to the algorithm, 8 patients (20%) with a QRS160ms [Group C] received a PPM. Among the EPS group: 9 patients (22.5%) with HV>65ms underwent PPM [group B2], while 11 patients with HV<65ms (27.5%) were discharged without PPM [group B1]. During a one-year follow-up only one patient required late PPM [group B1]. Mortality was higher among the subgroups with PPM [B2 and C] compared to the subgroups without a PPM [A and B1]: 4 vs. 1 patient accordingly. Conclusions: The presented electrophysiology-guided algorithm for patients with persistent LBBB after TAVR appears safe and efficient, with a modest incidence of PPM (17.6% of the total cohort) during hospitalization and a minimal need for late PPM at one year follow-up. Importantly, there was no excess of mortality among patients who were discharged without a pacemaker implantation. Thus, we suggest that the presented algorithm may serve as a reliable strategy to distinguish between individuals with new onset persistent LBBB after TAVR who require PPM compared to those in whom a PPM can be safely avoided.
- 24 May 2024
- Published by Oxford University Press (OUP) in EP Europace
- Vol. 26 (Supplement)
Open AccessElectrophysiology-guided algorithm for patients with conduction abnormalities post TAVR: one-year follow-up
Introduction: Transcatheter aortic valve replacement (TAVR) revolutionized the treatment of aortic stenosis [1]. Although TAVR is an effective treatment for AS patients, it is associated with high incidence of new-onset conduction disturbances and pacemaker implantations. The two most common conduction disturbances after TAVR are new onset left bundle branch block (LBBB) and high-degree atrioventricular block (HDAVB) [2]. While patients with HDAVB require a permanent pacemaker implantation (PPM), the management of LBBB is not completely established yet. According to the ESC 2021 guidelines, a PPM is indicated in patients with persistent HDAVB or new onset alternating BBB after TAVR. Yet, the recommendations regarding other conduction abnormalities are not well defined. In patients with persistent new onset LBBB, ambulatory continuous ECG monitoring or electrophysiology study (EPS) are recommended [3]. Purpose: To evaluate the clinical outcomes of patients with conduction disorders after TAVR who were managed according to electrophysiology-guided algorithm (Figure 1), including mortality, late pacemaker’s implantations, and heart failure hospitalizations. Predictors of periprocedural LBBB and HDAVB were also assessed. Methods: Retrospective population-based cohort study including all patients who developed new onset LBBB after TAVR at a tertiary University Medical Center from October 1, 2018, to December 31, 2022, and were managed according to specific electrophysiology-guided algorithm. Results: The study cohort included 230 consecutive patients who underwent TAVR. Mean age was 80.3 and 56.5% were females (Figure 2). Twenty patients (8.7%) developed HDAVB and required a PPM, whereas 40 patients (17.4%) developed persistent LBBB. According to the algorithm, 8 patients (20%) with a QRS160ms [Group C] received a PPM. Among the EPS group: 9 patients (22.5%) with HV>65ms underwent PPM [group B2], while 11 patients with HV<65ms (27.5%) were discharged without PPM [group B1]. During a one-year follow-up only one patient required late PPM [group B1]. Mortality was higher among the subgroups with PPM [B2 and C] compared to the subgroups without a PPM [A and B1]: 4 vs. 1 patient accordingly. Conclusions: The presented electrophysiology-guided algorithm for patients with persistent LBBB after TAVR appears safe and efficient, with a modest incidence of PPM (17.6% of the total cohort) during hospitalization and a minimal need for late PPM at one year follow-up. Importantly, there was no excess of mortality among patients who were discharged without a pacemaker implantation. Thus, we suggest that the presented algorithm may serve as a reliable strategy to distinguish between individuals with new onset persistent LBBB after TAVR who require PPM compared to those in whom a PPM can be safely avoided.
- 6 November 2023
- Published by Oxford University Press (OUP) in European Heart Journal
- Vol. 45 (5) , 379-388
Amiodarone and pulmonary toxicity in atrial fibrillation: a nationwide Israeli study
Background and Aims: Amiodarone-related interstitial lung disease (ILD) is the most severe adverse effect of amiodarone treatment. Most data on amiodarone-related ILD are derived from periods when amiodarone was given at higher doses than currently used. Methods: A nationwide population-based study was conducted among patients with incident atrial fibrillation (AF) between 1 December 1999 and 31 December 31 2021. Amiodarone-exposed patients were matched 1:1 with controls unexposed to amiodarone based on age, sex, ethnicity, and AF diagnosis duration. The final patient cohort included only matched pairs where amiodarone therapy was consistent throughout follow-up. Directed acyclic graphs and inverse probability treatment weighting (IPTW) modelling were used. Patients with either prior ILD or primary lung cancer (PLC) were excluded. The primary outcome was the incidence of any ILD. Secondary endpoints were death and PLC. Results: The final cohort included 6039 amiodarone-exposed patients who were matched with unexposed controls. The median age was 73.3 years, and 51.6% were women. After a mean follow-up of 4.2 years, ILD occurred in 242 (2.0%) patients. After IPTW, amiodarone exposure was not significantly associated with ILD [hazard ratio (HR): 1.45, 95% confidence interval (CI): 0.97, 2.44, P = 0.09]. There was a trivial higher relative risk of ILD among amiodarone-exposed patients between Years 2 and 8 of follow-up [maximal risk ratio (RR): 1.019]. Primary lung cancer occurred in 97 (0.8%) patients. After IPTW, amiodarone was not associated with PLC (HR: 1.18, 95% CI: 0.76, 2.08, P = 0.53). All-cause death occurred in 2185 (18.1%) patients. After IPTW, amiodarone was associated with reduced mortality risk (HR: 0.65, 95% CI: 0.60, 0.72, P < 0.001). The results were consistent across a variety of sensitivity analyses. Conclusion: In a contemporary AF population, low-dose amiodarone was associated with a trend towards increased risk of ILD (15%-45%) but a clinically negligible change in absolute risk (maximum of 1.8%), no increased risk of PLC, and a lower risk of all-cause mortality.
- 6 November 2023
- Published by Oxford University Press (OUP) in European Heart Journal
- Vol. 45 (5) , 379-388
Amiodarone and pulmonary toxicity in atrial fibrillation: a nationwide Israeli study
Background and Aims: Amiodarone-related interstitial lung disease (ILD) is the most severe adverse effect of amiodarone treatment. Most data on amiodarone-related ILD are derived from periods when amiodarone was given at higher doses than currently used. Methods: A nationwide population-based study was conducted among patients with incident atrial fibrillation (AF) between 1 December 1999 and 31 December 31 2021. Amiodarone-exposed patients were matched 1:1 with controls unexposed to amiodarone based on age, sex, ethnicity, and AF diagnosis duration. The final patient cohort included only matched pairs where amiodarone therapy was consistent throughout follow-up. Directed acyclic graphs and inverse probability treatment weighting (IPTW) modelling were used. Patients with either prior ILD or primary lung cancer (PLC) were excluded. The primary outcome was the incidence of any ILD. Secondary endpoints were death and PLC. Results: The final cohort included 6039 amiodarone-exposed patients who were matched with unexposed controls. The median age was 73.3 years, and 51.6% were women. After a mean follow-up of 4.2 years, ILD occurred in 242 (2.0%) patients. After IPTW, amiodarone exposure was not significantly associated with ILD [hazard ratio (HR): 1.45, 95% confidence interval (CI): 0.97, 2.44, P = 0.09]. There was a trivial higher relative risk of ILD among amiodarone-exposed patients between Years 2 and 8 of follow-up [maximal risk ratio (RR): 1.019]. Primary lung cancer occurred in 97 (0.8%) patients. After IPTW, amiodarone was not associated with PLC (HR: 1.18, 95% CI: 0.76, 2.08, P = 0.53). All-cause death occurred in 2185 (18.1%) patients. After IPTW, amiodarone was associated with reduced mortality risk (HR: 0.65, 95% CI: 0.60, 0.72, P < 0.001). The results were consistent across a variety of sensitivity analyses. Conclusion: In a contemporary AF population, low-dose amiodarone was associated with a trend towards increased risk of ILD (15%-45%) but a clinically negligible change in absolute risk (maximum of 1.8%), no increased risk of PLC, and a lower risk of all-cause mortality.
- Open Access
- 24 April 2023
- Published by Wiley
The association between seasonality and the incidence of permanent pacemaker implantations due to atrioventricular block
Background: Previous studies described a higher prevalence of cardiovascular comorbidities during the winter season. Data regarding seasonal association of atrioventricular (AV) block are scarce. Methods: A retrospective cohort analysis of all patients admitted to a tertiary medical center with AV block requiring a permanent pacemaker (PPM) implantation between 2006-2017 was performed. In a time-series analysis, the seasonal incidence of PPM implementations due to AV block was assessed and adjusted for meteorological factors. The association between the weekly incidence of PPM implantations and the weekly rates of influenza as reported by the Israel Center of Disease Control (ICDC) were also assessed. Result: The study population included 759 patients. Mean age was 76.1 years and 55% were males. Most of the patients (34.1%) were admitted in the winter season. In multivariate analysis, there was a significantly higher incidence of PPM implantations among men during the winter season as compared to the fall season (Adjusted IRR [Incidence Rate-Ratio] 1.40, 95% CI 1.05;1.88; pConclusion: In the present analysis the incidence of PPM implantations due to AV block was higher among men during the winter season and correlated with high influenza illness rates. Further prospective and larger studies are required to assess these findings.
- 24 April 2023
- Published by Wiley
Open AccessThe association between seasonality and the incidence of permanent pacemaker implantations due to atrioventricular block
Background: Previous studies described a higher prevalence of cardiovascular comorbidities during the winter season. Data regarding seasonal association of atrioventricular (AV) block are scarce. Methods: A retrospective cohort analysis of all patients admitted to a tertiary medical center with AV block requiring a permanent pacemaker (PPM) implantation between 2006-2017 was performed. In a time-series analysis, the seasonal incidence of PPM implementations due to AV block was assessed and adjusted for meteorological factors. The association between the weekly incidence of PPM implantations and the weekly rates of influenza as reported by the Israel Center of Disease Control (ICDC) were also assessed. Result: The study population included 759 patients. Mean age was 76.1 years and 55% were males. Most of the patients (34.1%) were admitted in the winter season. In multivariate analysis, there was a significantly higher incidence of PPM implantations among men during the winter season as compared to the fall season (Adjusted IRR [Incidence Rate-Ratio] 1.40, 95% CI 1.05;1.88; pConclusion: In the present analysis the incidence of PPM implantations due to AV block was higher among men during the winter season and correlated with high influenza illness rates. Further prospective and larger studies are required to assess these findings.